Navidea Biopharmaceuticals Stock News

Gainers HeartBeam, Inc. (NASDAQ: BEAT) shares jumped 85.6% to close at $2.32 on Thursday after the company announced its patent for a 12-lead electrocardiogram patch monitor intended for detection of

Gainers HeartBeam, Inc. (NASDAQ: BEAT) shares surged 58% to $1.96 after the company announced its patent for a 12-lead electrocardiogram patch monitor intended for detection of acute coronary syndrom

Gainers Aditxt, Inc. (NASDAQ: ADTX) rose 54.3% to $28.56 in pre-market trading following effect of 1:50 reverse stock split. Akerna Corp. (NASDAQ: KERN) shares rose 37.6% to $0.1789 in pre-market tra

Navidea Biopharmaceuticals, Inc. (NYSE:NAVB ) Q2 2022 Earnings Conference Call September 8, 2022 4:00 PM ET Company Participants Michael Rosol – CMO Alex Cappello - Vice Chair Erika Eves - VP, Finan

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immuno

Navidea Biopharmaceuticals, Inc. (NYSE:NAVB ) Q1 2022 Results Conference Call May 12, 2022 5:00 PM ET Company Participants Michael Rosol - CMO Erika Eves - VP, Finance & Administration Conference Call

Here's what you need to know about trading penny stocks on April 19th The post Hot Penny Stocks to Buy? 3 to Watch As CMPI Stock Shoots Up 320% appeared first on Penny Stocks to Buy, Picks, News and I

Navidea Biopharmaceuticals, Inc. (NAVB) Q4 2021 Results - Earnings Call Transcript

Navidea Biopharmaceuticals Inc. (AMEX:NAVB) price closed higher on Monday, February 07, jumping 23.19% above its previous close. >> 7 Top Picks for the Post-Pandemic Economy > 7 Top Picks for the Post-Pandemic Economy

Gainers Nuvectis Pharma, Inc. (NASDAQ: NVCT ) shares surged 144.6% to close at $7.95 on Monday. The company, on Friday, priced its IPO at $5 per share. Anghami Inc. (NASDAQ: ANGH ) shares climbed 62.5% to close at $19.50 following its recent listing on NASDAQ. Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL ) surged 51.4% to settle at $1.62. Kaival Brands Innovations recently announced the U.S. Court of Appeals for the Eleventh Circuit has granted a judicial stay of the marketing denial order previously issued by the FDA to Bidi Vapor in September 2021. Origin Agritech Limited (NASDAQ: SEED ) gained 34.5% to settle at $6.39 after the company said it expects FY22 sales to exceed RMB150 million. Bakkt Holdings, Inc. (NASDAQ: BKKT ) shares jumped 34% to close at $5.80. Luokung Technology Corp. (NASDAQ: LKCO ) gained 24.3% to close at $0.63. Luokung recently announced the receipt of Nasdaq notification regarding minimum bid price deficiency. Navidea Biopharmaceuticals, Inc. (NYSE: NAVB ) surged 23.2% to settle at $0.8870 after the company announced a research agreement with the University of Pennsylvania evaluating Tc99m tilmanocept as a prognostic marker for glioblastoma.

Navidea Biopharmaceuticals Inc (NYSE: NAVB ) has signed a Sponsored Research Agreement with the University of Pennsylvania to evaluate the use of Tc99m tilmanocept imaging in glioblastoma as a prognostic agent for tumor growth rate and overall survival. Glioblastoma (GBM) is the most aggressive and most common primary central Full story available on Benzinga.com

Navidea Biopharmaceuticals (NAVB) is trading ~20% higher on Monday after announcing that the company and the University of Pennsylvania entered into a sponsored research agreement…

Navidea Biopharmaceuticals (NAVB) announced on Thursday that it received a letter from the NYSE American stating that the company has failed to comply with the continued listing

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Merck Announces Publication Of Positive Data From Late-Stage Study Of Oral COVID-19 Antiviral Treatmen

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (Navidea or the Company), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it has achieved full enrollment in its NAV3-35 Phase 2b clinical study titled Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging with Tc99m Tilmanocept. Establishing a healthy subject database is necessary to create a quantitative method f